Ethos Technologies Inc. Class A Common Stock's Drug in the FDA Approval Process
This section highlights FDA-related milestones and regulatory updates for drugs developed by Ethos Technologies Inc. Class A Common Stock (LIFE).
Over the past two years, Ethos Technologies Inc. Class A Common Stock has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as
Efzofitimod. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend.
Efzofitimod FDA Regulatory Events
Efzofitimod is a drug developed by Ethos Technologies Inc. Class A Common Stock for the following indication: Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD).
This drug is under review by the U.S. Food and Drug Administration (FDA).
Below is a timeline of key regulatory milestones for this therapy.
- Drug:
- Efzofitimod
- Announced Date:
- September 1, 2026
- Indication:
- Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)
Announcement
aTyr Pharma, Inc. today provided an update on the expected timing of a response from the U.S. Food and Drug Administration (FDA) related to the protocol the Company submitted in June 2026 for a planned Phase 3 study of efzofitimod in patients with chronic, symptomatic pulmonary sarcoidosis with restrictive lung disease.
Read Announcement- Drug:
- Efzofitimod
- Announced Date:
- July 15, 2026
- Indication:
- Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)
Announcement
aTyr Pharma, Inc. announced that the Company will present a subgroup analysis of the Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis, a major form of interstitial lung disease, at the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) 2026 Congress, which is scheduled to take place July 15 – 17, 2026, in Porto, Portugal.
AI Summary
aTyr Pharma said it will present a subgroup analysis from its Phase 3 EFZO-FIT™ study of efzofitimod at the 2026 WASOG Congress in Porto, Portugal, from July 15 to 17, 2026. The analysis focuses on patients with pulmonary sarcoidosis, a serious form of interstitial lung disease that can make breathing harder over time.
According to the company, patients with restrictive lung disease showed clinically meaningful improvement in forced vital capacity, or FVC, along with better results on multiple patient-reported outcome measures when treated with 5.0 mg/kg efzofitimod compared with placebo. These findings suggest the drug may help improve lung function and symptoms in this hard-to-treat group.
aTyr also said it submitted a protocol to the FDA in June 2026 for a planned Phase 3 study in patients with chronic, symptomatic pulmonary sarcoidosis and restrictive lung disease. The poster details will be available on the company’s website after the presentation.
Read Announcement
Ethos Technologies Inc. Class A Common Stock FDA Events - Frequently Asked Questions
As of now, Ethos Technologies Inc. Class A Common Stock (LIFE) has not received any FDA approvals for its therapy in the last two years.
In the past two years, Ethos Technologies Inc. Class A Common Stock (LIFE) has reported FDA regulatory activity for Efzofitimod.
The most recent FDA-related event for Ethos Technologies Inc. Class A Common Stock occurred on September 1, 2026, involving Efzofitimod. The update was categorized as "Provided Update," with the company reporting: "aTyr Pharma, Inc. today provided an update on the expected timing of a response from the U.S. Food and Drug Administration (FDA) related to the protocol the Company submitted in June 2026 for a planned Phase 3 study of efzofitimod in patients with chronic, symptomatic pulmonary sarcoidosis with restrictive lung disease."
Currently, Ethos Technologies Inc. Class A Common Stock has one therapy (Efzofitimod) targeting the following condition: Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD).
More FDA Event Resources from MarketBeat
Companies With Recent FDA Events
FDA Event Stage Terminology & Abbreviation Guide
- NDA: New Drug Application
- ANDA: Abbreviated New Drug Application
- sNDA: Supplemental New Drug Application
- BLA: Biologics License Application
- sBLA: Supplemental Biologics License Application
- FDA Approved: Approved by the FDA
- EMA: European Medicines Agency
- CE Mark: European Union Certification
- NMPA: China National Medical Products Administration
- MHLW: Japanese Ministry of Health
- FDA Meeting: Consultation with FDA
- Pre-IND: Pre-Investigational New Drug Meeting
- Breakthrough Therapy: Special FDA designation for promising therapies
- Fast Track: Accelerated FDA approval pathway
- Orphan Drug: Designation for rare disease treatments
- RPD: Rare Pediatric Disease Designation
- RMAT: Regenerative Medicine Advanced Therapy
- DSMB Review: Data Safety Monitoring Board Review
- IDMC Review: Independent Data Monitoring Committee
- MAA: MHRA Marketing Authorization Application
- RTF: Refusal to File (Rejected Application)
- 510(k): FDA Clearance for Medical Devices
- Rolling Submission: Staggered regulatory review process
FDA progress for NASDAQ:LIFE last updated on 9/2/2026 by MarketBeat.com Staff. We continuously monitor for new FDA events and market data.
